| Background : Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed the efficacy of different chemotherapies in randomized controlled clinical trials for platinum sensitive recurrent ovarian cancer.Objectives: (1) To determine the efficacy of chemotherapy in comparison with another chemotherapy in the treatment of patients with platinum-sensitive recurrent ovarian cancer relapsing after 6 months of being treatment-free.(2) To determine the significant adverse outcomes associated with different chemotherapies for patients.Search strategy: We searched the Cochrane library, MEDLINE, EMBASE, China National Knowledge Infrastruture, and reference lists of articles, and we contacted principal investigators.Selection criteria: Randomised trials comparing any chemotherapies with other chemotherapies in recurrent ovarian cancer; previously received platinum-based chemotherapy; been treatment-free for more than 6 months.Data collection and analysis: Reviewers independently assessed trial quality and extracted data.Main results: Five trials involving 1555 people aged above 18 years were included. The overall quality of the included trials was variable. People in Paclitaxel plus platinum-based chemotherapy group have a higher response to assigned treatment than those in conventional platinum-based chemothereapy group (RR=1.29, 95%CI 1.08-1.54).For the quality-of-life assessment, the worst scores and the areas under the curve for nausea and vomiting differ between treatment groups,which was worse for the patients receiving conventional platinum-based chemotherapy. In one trial, median PFS was 8.6 months for gemcitabine-carboplatin (95% CI 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P=0.0032]). The response rate for the... |
PDF Full Text Request